Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) EBITDA Margin (2016 - 2023)

RedHill Biopharma has reported EBITDA Margin over the past 12 years, most recently at 2992.87% for Q2 2023.

  • Quarterly EBITDA Margin rose 292904.0% to 2992.87% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 42.99% through Jun 2023, up 7858.0% year-over-year, with the annual reading at 2776.92% for FY2025, 270373.0% down from the prior year.
  • EBITDA Margin was 2992.87% for Q2 2023 at RedHill Biopharma, up from 808.0% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 2992.87% in Q2 2023 and troughed at 808.0% in Q1 2023.
  • The 5-year median for EBITDA Margin is 120.95% (2021), against an average of 349.19%.
  • Year-over-year, EBITDA Margin plummeted -151360bps in 2021 and then soared 292904bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 739.87% in 2019, then tumbled by -88bps to 91.83% in 2020, then tumbled by -798bps to 641.43% in 2021, then increased by 8bps to 591.81% in 2022, then soared by 606bps to 2992.87% in 2023.
  • Per Business Quant, the three most recent readings for RDHL's EBITDA Margin are 2992.87% (Q2 2023), 808.0% (Q1 2023), and 591.81% (Q4 2022).